Cargando…

Thulium laser versus standard transurethral resection of the prostate: A randomized prospective trial

Detalles Bibliográficos
Autores principales:	Dubey, Deepak, Muruganandham, K.
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2008
Materias:	Uroscan
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684372/ https://www.ncbi.nlm.nih.gov/pubmed/19468488

Ejemplares similares

What is the treatment of choice for bulbar urethral strictures which are not an indication for visual internal urethrotomy?
por: Dubey, Deepak, et al.
Publicado: (2008)

Does dutasteride reduce perioperative blood loss and postoperative complications after transurethral resection of the prostate?
por: Shanmugasundaram, R., et al.
Publicado: (2007)

Transurethral ethanol ablation for symptomatic benign prostatic hyperplasia
por: Gautam, Gagan, et al.
Publicado: (2007)

T1 bladder cancer on restaging transurethral resection should be treated with immediate cystectomy
por: Gautam, Gagan, et al.
Publicado: (2007)

The current role of Active Surveillance in early prostate cancer
por: Shrinivas, R. P., et al.
Publicado: (2009)

Malignant ureteral obstruction: Whether decompression really improves patient outcomes and quality of life?
por: Muruganandham, K., et al.
Publicado: (2008)

Does treatment rate impact the efficacy of extracorporeal shock wave lithotripsy for kidney or ureteral stones?
por: Muruganandham, K., et al.
Publicado: (2007)

Comparison between thulium laser resection of prostate and transurethral plasmakinetic resection of prostate or transurethral resection of prostate
por: DeCao, Hong, et al.
Publicado: (2015)

Ureteroilleal anastomosis in orthotopic ileal neobladders: Does technique matter?
por: Gupta, Parag, et al.
Publicado: (2008)

Comparison of multiparametric ultrasound versus multiparametric magnetic resonance imaging for diagnosis of carcinoma prostate: The CADMUS trial
por: Tarigopula, Vivek
Publicado: (2022)

Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial
por: Singh, Kirti
Publicado: (2023)

POUT trial: Perioperative chemotherapy in upper tract urothelial carcinoma – A standard of care?
por: Ranjan, Satish Kumar
Publicado: (2020)

PROFOUND trial –a new era in targeted therapeutics for prostate carcinoma
por: Tosh, Jyoti Mohan
Publicado: (2022)

Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial
por: Singh, Kirti
Publicado: (2022)

TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
por: Kumar, Gautam
Publicado: (2020)

Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020)

PROMPTS Trial: Screening spinal magnetic resonance imaging in castration-resistant prostate cancer
por: Pattnaik, Soumya Shivasis
Publicado: (2023)

Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?
por: Kumar, Naveen
Publicado: (2021)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

Comparing outcomes between neoadjuvant hormonal therapy followed by prostatectomy versus upfront prostatectomy in high-risk prostate cancer: The road ahead
por: Bhargava, Priyank
Publicado: (2023)

Is lap nephrectomy superior to open? A randomized trial
por: Kumar, Anup, et al.
Publicado: (2008)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis
por: Kumar, Gautam
Publicado: (2020)

Open versus robotic radical cystectomy: Results from the 3-year follow-up of the RAZOR trial
por: Nagasubramanian, Santhosh
Publicado: (2020)

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

Pharmacological prophylaxis for venous thromboembolism: Is it time to change the gold standard?
por: Kumaraswamy, Santosh
Publicado: (2021)

Defining the role of antioxidants in the prevention of prostate cancer
por: Pathak, Hemant R., et al.
Publicado: (2009)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Virtual versus real cystoscopy
por: Yadav, Rajiv, et al.
Publicado: (2007)

Long-term follow-up results of nivolumab plus cabozantinib versus sunitinib for advanced renal cell cancer: Checkmate 9ER trial
por: Tarigopula, Vivek
Publicado: (2022)

Endocrine treatment in advanced prostate cancer: When to start?
por: Choudhrie, A. V., et al.
Publicado: (2009)

Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial
por: Hashim, Hashim, et al.
Publicado: (2020)

Safety and efficacy of active surveillance in patients with localized prostate cancer
por: Mavuduru, Ravimohan, et al.
Publicado: (2008)

Prostate cancer treatment does not increase the risk of cardiovascular events
por: Khochikar, Makarand V.
Publicado: (2007)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

A novel approach to management of nocturia in patients with benign prostatic hyperplasia
por: Sengottayan, Vengetesh K., et al.
Publicado: (2009)

Is incidence of prostate cancer higher in patients with end stage renal disease?
por: Khochikar, Makarand V.
Publicado: (2007)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_6dlb2mdrnkuf2doaa5tilkgqj6